DUBLIN--(BUSINESS WIRE)--The "Pharmaceutical Drug Development Sector Scorecard, Q3 2021 Update - Thematic Research" report has been added to ResearchAndMarkets.com's offering.
AI was one of the most dynamic technology themes for pharma in 2021, with companies forging additional strategic partnerships with AI vendors, particularly in drug development, as well as participating in funding rounds for AI start-ups.
Several big pharma companies saw their AI scores increase from 4 to 5, including Bristol Myers Squibb (BMS), AstraZeneca, and Johnson and Johnson (J&J), mainly due to additional strategic partnerships and funding activity with AI vendors. BMS also announced in August 2021 that it had secured a license to an immune-modulating drug candidate created by Exscientia.
Other areas of drug development that had significant activity in 2021 include immuno-oncology and genomics, highlighting that despite the pressures that COVID-19 placed on the pharma industry, companies are still investing in innovative areas of R&D.
There were several mergers and acquisitions (M&A) in immuno-oncology and genomics in 2021, including the acquisition of Five Prime Therapeutics and TeneoBio by Amgen, and Translate Bio by Sanofi.
Microbiome-related activity by big pharma has been relatively quiet in recent years, but Takeda announced in August 2021 that it was to progress a new candidate into Phase I trials in 2022. One of the most important score decreases was for Astellas in regenerative medicine, following the death of a trial participant for its gene therapy AT132.
The thematic scoring methodology is designed to identify tomorrow's leaders rather than today's incumbents, based on their competitive position in the 10 most important themes impacting the landscape.
Scope
- this Drug Development Thematic Scorecard report provides a top-down, comprehensive future outlook for key players in the drug development sector over the next two to four years.
- These themes are Virtual Care, Rare Disease, Orphan Designated Drugs, Strategic Alliances, Real-world Evidence, AI, ESG, Cybersecurity, Cloud Computing, and Blockchain.
- The scorecard includes 54 companies from across the industry, including biopharmaceutical companies, biosimilar and generic manufacturers, contract development and manufacturing organizations (CDMOs), and contract research organizations (CROs).
- The methodology contains detailed information on what data sources were used to generate the thematic scores for each company.
Reasons to Buy
- Identify the key clinical trial themes for the next 2-4 years and learn how they will impact the market.
- Understand which key themes should be addressed to drive share price.
- Understand which companies are best positioned for success within critical themes and why.
- Learn which companies have underinvested in key themes and are most vulnerable to disruption.
- Help companies adapt their strategy to anticipate and benefit from these themes as they play out.
- Help identify future winners and losers in drug development to inform partnership strategies.
Key Topics Covered:
- Executive Summary
- Introduction
- Pharma Theme Map
- Drug Development Scorecard
- Company Screen
- Thematic Screen
- Valuation Screen
- Our Thematic Research Methodology
- How Our Pharma Scores Are Generated
Companies Mentioned
- Takeda Pharmaceutical Co Ltd
- Merck & Co Inc
- AstraZeneca Plc
- Bristol-Myers Squibb Co
- Pfizer Inc
- Johnson & Johnson
- Boehringer Ingelheim
- Parexel International Corp
- F. Hoffmann-La Roche Ltd
- Novartis AG
- GlaxoSmithKline Plc
- Bayer AG
- Eli Lilly and Co
- IQVIA Holdings Inc
- AbbVie Inc
- Merck KGaA
- Novo Nordisk AS
- Catalent Inc
- Gilead Sciences Inc
- Thermo Fisher Scientific Inc
- Astellas
- Biogen Inc
- Cipla Ltd
- Lonza Group Ltd
- Amgen Inc
- Daiichi Sankyo Co Ltd
- Vertex Pharmaceuticals Inc
- WuXi AppTec Co Ltd
- Charles River Laboratories International Inc
- CSL Ltd
- Reliance Life Sciences Pvt Ltd
- Sanofi
- Innovent Biologics Inc
- Otsuka
- Teva Pharmaceutical Industries Ltd
- UCB
- Dr. Reddy's Laboratories Ltd
- Regeneron Pharmaceuticals Inc
- Samsung Bioepis Co Ltd
- Sun Pharmaceutical Industries Ltd
- Biocad
- Cadila Pharmaceuticals Ltd
- Celltrion Inc
- Coherus BioSciences Inc
- CSPC Pharmaceutical Group Ltd
- Generium
- Intas Pharmaceuticals Ltd
- Lupin Ltd
- Perrigo Co Plc
- Pharmaceutical Product Development LLC
- Seagen Inc
- Shanghai Henlius Biotech Inc
- Viatris Inc
- Zydus Cadila
For more information about this report visit https://www.researchandmarkets.com/r/mxhkwo
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900